WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H562328
CAS#: 388592-44-7
Description: CK-869 is an inhibitor of human and bovine actin-related protein 2/3 (Arp2/3) complex.
Hodoodo Cat#: H562328
Name: CK-869
CAS#: 388592-44-7
Chemical Formula: C17H16BrNO3S
Exact Mass: 393.00
Molecular Weight: 394.280
Elemental Analysis: C, 51.79; H, 4.09; Br, 20.27; N, 3.55; O, 12.17; S, 8.13
Synonym: CK-869; CK 869; CK869; CK-0157869; CK 0157869; CK0157869;
IUPAC/Chemical Name: 2-(3-Bromophenyl)-3-(2,4-dimethoxyphenyl)-4-thiazolidinone
InChi Key: MVWNPZYLNLATCH-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H16BrNO3S/c1-21-13-6-7-14(15(9-13)22-2)19-16(20)10-23-17(19)11-4-3-5-12(18)8-11/h3-9,17H,10H2,1-2H3
SMILES Code: O=C1N(C2=CC=C(OC)C=C2OC)C(C3=CC=CC(Br)=C3)SC1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 394.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Yamagishi Y, Oya K, Matsuura A, Abe H. Use of CK-548 and CK-869 as Arp2/3 complex inhibitors directly suppresses microtubule assembly both in vitro and in vivo. Biochem Biophys Res Commun. 2018 Feb 12;496(3):834-839. doi: 10.1016/j.bbrc.2018.01.143. Epub 2018 Feb 1. PubMed PMID: 29395083.
2: Beckham Y, Vasquez RJ, Stricker J, Sayegh K, Campillo C, Gardel ML. Arp2/3 inhibition induces amoeboid-like protrusions in MCF10A epithelial cells by reduced cytoskeletal-membrane coupling and focal adhesion assembly. PLoS One. 2014 Jun 26;9(6):e100943. doi: 10.1371/journal.pone.0100943. eCollection 2014. PubMed PMID: 24967897; PubMed Central PMCID: PMC4072770.
3: Ilatovskaya DV, Chubinskiy-Nadezhdin V, Pavlov TS, Shuyskiy LS, Tomilin V, Palygin O, Staruschenko A, Negulyaev YA. Arp2/3 complex inhibitors adversely affect actin cytoskeleton remodeling in the cultured murine kidney collecting duct M-1 cells. Cell Tissue Res. 2013 Dec;354(3):783-92. doi: 10.1007/s00441-013-1710-y. Epub 2013 Sep 15. PubMed PMID: 24036843; PubMed Central PMCID: PMC3850072.
4: Hetrick B, Han MS, Helgeson LA, Nolen BJ. Small molecules CK-666 and CK-869 inhibit actin-related protein 2/3 complex by blocking an activating conformational change. Chem Biol. 2013 May 23;20(5):701-12. doi: 10.1016/j.chembiol.2013.03.019. Epub 2013 Apr 25. PubMed PMID: 23623350; PubMed Central PMCID: PMC3684959.